Illumina launches compact, low-cost gene sequencing devices
By Puyaan Singh and Bhanvi Satija
Oct 9 (Reuters) -Medical equipment makerIllumina ILMN.O on Wednesday announced its new series of smaller, low-cost benchtop gene sequencers, a move that will make sequencing accessible to more research and testing labs.
New generation sequencers, like Illumina's MiSeq devices, help determine the sequence of DNA or RNA to study genetic variation associated with diseases and diagnose rare genetic conditions.
Unlike Illumina's NovaSeq X devices, which are as large as a Xerox copier and designed for in-depth sequencing, the new MiSeq i100 and MiSeq i100 Plus systems are compact enough to be placed on benchtops, allowing smaller labs, which typically outsource gene sequencing, to have these capabilities in-house.
The U.S. list price for the NovaSeq X devices starts at just under $1 million compared to the MiSeq i100, which is priced at $49,000 in the United States.
The i100 Plus system, designed to process a greater number of samples, has a list price of $109,000.
The new MiSeq devices can produce results in just four hours, four times faster than the older MiSeq sequencer and is priced at $99,000.
CEO Jacob Thaysen stated that the new sequencers represent a billion-dollar opportunity for Illumina.
"Instead of having a PhD to run the sequencer, we can now have lab techs do it; instead of waiting overnight for sequencing, we can do it in one day," Thaysen said.
MiSeq i100 devices will offer 18 different programs accessible on the instrument and in the cloud.
These include panels for detecting respiratory and urinary pathogens, conducting influenza A and B surveillance, and utilizing multiple cancer research panels.
The San Diego-based company said it is taking pre-orders for the systems and will start shipping them globally in 2025.
Illumina said the reagents used in these devices can be shipped and stored at room temperature, eliminating the need for costly and bulky freezers.
Reporting by Puyaan Singh and Bhanvi Satija in Bengaluru; Editing by Tasim Zahid
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
